Last reviewed · How we verify
lorlatinib plus chemotherapy
Lorlatinib is an ALK tyrosine kinase inhibitor combined with chemotherapy to target ALK-positive cancers while enhancing cytotoxic effects.
Lorlatinib is an ALK tyrosine kinase inhibitor combined with chemotherapy to target ALK-positive cancers while enhancing cytotoxic effects. Used for ALK-positive non-small cell lung cancer (NSCLC), ALK-positive advanced or metastatic lung cancer.
At a glance
| Generic name | lorlatinib plus chemotherapy |
|---|---|
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University |
| Drug class | ALK tyrosine kinase inhibitor (combination therapy) |
| Target | ALK (anaplastic lymphoma kinase), ROS1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Lorlatinib selectively inhibits anaplastic lymphoma kinase (ALK) and ROS1, blocking aberrant signaling in ALK-fusion positive tumors. The addition of chemotherapy provides complementary cytotoxic activity to enhance overall anti-tumor efficacy and potentially overcome resistance mechanisms.
Approved indications
- ALK-positive non-small cell lung cancer (NSCLC)
- ALK-positive advanced or metastatic lung cancer
Common side effects
- Peripheral edema
- Fatigue
- Nausea
- Constipation
- Myelosuppression (from chemotherapy component)
- Neuropathy
Key clinical trials
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion (EARLY_PHASE1)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer (PHASE2)
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) (PHASE1, PHASE2)
- NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) (PHASE1)
- Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics (PHASE4)
- Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma (PHASE3)
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: